The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

U	INITED STATES SECURIT			OMB APPROVAL
		ngton, D.C. 20549		OMB Number: 3235-0076
		FORM D		Estimated average burden
	Notice of Exem	pt Offering of Secu	rition	hours per response: 4.00
	Notice of Exem	ipt Onering of Secu	nnes	
1. Issuer's Identity				
CIK (Filer ID Number)	Previous Names	None	Entity Type	
<u>0001517681</u>	Propanc Heal	th Group Corp	X Corporation	
Name of Issuer		th Group Corporation	Limited Partnersh	ip
Propanc Biopharma, Inc.			H	
Jurisdiction of Incorporation/Orga	anization		Limited Liability C	
DELAWARE			General Partnersh	nip
Year of Incorporation/Organizatio	חנ		Business Trust	
X Over Five Years Ago			Other (Specify)	
Within Last Five Years (Speci	fy Year)			
Yet to Be Formed				
2. Principal Place of Business a	and Contact Information			
Name of Issuer				
Propanc Biopharma, Inc.				
Street Address 1		Street Address 2		
302, 6 BUTLER STREET				
City	State/Province/Country	ZIP/PostalCode	Phone Number of Is	ssuer
CAMBERWELL, VIC	AUSTRALIA	3124	+61-03-9882-0780	
3. Related Persons				
Last Name	First Name		Middle Name	
Nathanielsz	James			
Street Address 1	Street Address 2			
302, 6 Butler Street				
City	State/Province/Co	ountry	ZIP/PostalCode	
Camberwell, VIC	AUSTRALIA		3124	
Relationship: X Executive Office	r X Director Promoter			
Clarification of Response (if Nece	ssary):			
Chief Executive Officer and Chief Fi	nancial Officer			
Last Name	First Name		Middle Name	
Kenyon	Julian			
Street Address 1	Street Address 2			
302, 6 Butler Street				
City	State/Province/Co	ountry	ZIP/PostalCode	
Camberwell, VIC	AUSTRALIA		3124	
Relationship: X Executive Officer	r X Director Promoter			
Clarification of Response (if Nece	ssary):			
Chief Scientific Officer				
Last Name	First Name		Middle Name	
Zelinger	Josef			
Street Address 1	Street Address 2			
302, 6 Butler Street				
City	State/Province/Co	ountry	ZIP/PostalCode	
Camberwell, VIC	AUSTRALIA		3124	

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Investing	Hospitals & Physicians	
Investment Banking	X Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as an investment company under	Manufacturing Real Estate	
the Investment Company Act of 1940?		Airlines & Airports
Yes		Lodging & Conventions
Other Banking & Financial Services	REITS & Finance	Other Travel
Business Services	Residential	Other
Energy	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act	Section 3(c)
_	Section 3(c)(1)	Section 3(c)(9)
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
X Rule 506(b) Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)
Securities Act Section 4(a)(5)		
	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

7. Type of Filing	
X New Notice Date of First Sale 2023-08-16 First Sale Yet to Occur	r
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to last more than one year?	s X No
9. Type(s) of Securities Offered (select all that apply)	
Equity	Pooled Investment Fund Interests
X Debt	Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other F Acquire Security	
10. Business Combination Transaction	
Is this offering being made in connection with a business combination to or exchange offer?	ransaction, such as a merger, acquisition
Clarification of Response (if Necessary):	
11. Minimum Investment	
Minimum investment accepted from any outside investor \$55,000 USD	
12. Sales Compensation	
Recipient	Recipient CRD Number 🔀 None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
Street Address 1	Street Address 2
City	State/Province/Country ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US
13. Offering and Sales Amounts	
Total Offering Amount \$55,000 USD or Indefinite	
Total Amount Sold \$55,000 USD	
Total Remaining to be Sold \$0 USD or Indefinite	
Clarification of Response (if Necessary):	
14. Investors	
\square such non-accredited investors who already have invested in the offer	ons who do not qualify as accredited investors, and enter the number of pring. The sold to persons who do not qualify as accredited investors, enter the
15. Sales Commissions & Finder's Fees Expenses	
Provide separately the amounts of sales commissions and finders fees of check the box next to the amount.	expenses, if any. If the amount of an expenditure is not known, provide an estimate and
Sales Commissions \$0 USD Estimate	
Finders' Fees \$0 USD Estimate	
Clarification of Response (if Necessary):	
16. Use of Proceeds	

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration go accepting of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Propanc Biopharma, Inc.	/s/ James Nathanielsz	James Nathanielsz	Chief Executive Officer and Chief Financial Officer	2023-08-31

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.